BE2014C068I2 - - Google Patents

Info

Publication number
BE2014C068I2
BE2014C068I2 BE2014C068C BE2014C068C BE2014C068I2 BE 2014C068 I2 BE2014C068 I2 BE 2014C068I2 BE 2014C068 C BE2014C068 C BE 2014C068C BE 2014C068 C BE2014C068 C BE 2014C068C BE 2014C068 I2 BE2014C068 I2 BE 2014C068I2
Authority
BE
Belgium
Prior art keywords
present
immunoglobulin
humanized
human
humanized immunoglobulin
Prior art date
Application number
BE2014C068C
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24814673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C068(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BE2014C068I2 publication Critical patent/BE2014C068I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2014C068C 1996-08-15 2014-11-12 BE2014C068I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/700,737 US7147851B1 (en) 1996-08-15 1996-08-15 Humanized immunoglobulin reactive with α4β7 integrin

Publications (1)

Publication Number Publication Date
BE2014C068I2 true BE2014C068I2 (fr) 2017-09-22

Family

ID=24814673

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C068C BE2014C068I2 (fr) 1996-08-15 2014-11-12

Country Status (19)

Country Link
US (3) US7147851B1 (fr)
EP (2) EP1710314A1 (fr)
JP (3) JP4171071B2 (fr)
CN (1) CN100406562C (fr)
AT (1) ATE321788T1 (fr)
AU (1) AU730326C (fr)
BE (1) BE2014C068I2 (fr)
BR (1) BRPI9711079B1 (fr)
CA (1) CA2263106C (fr)
DE (1) DE69735596T3 (fr)
DK (1) DK0918797T4 (fr)
ES (1) ES2262186T5 (fr)
IL (3) IL128052A0 (fr)
LT (1) LTC0918797I2 (fr)
LU (1) LU92596I2 (fr)
NZ (1) NZ334226A (fr)
PT (1) PT918797E (fr)
SI (1) SI0918797T2 (fr)
WO (1) WO1998006248A2 (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
AU2011226857B2 (en) * 1998-05-13 2013-09-19 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
ATE316798T1 (de) * 1998-11-25 2006-02-15 Us Gov Health & Human Serv Antagoniste des alpha-e-beta-7 integrins als therapeutische agenzien gegen entzündungskrankheiten
IL145898A0 (en) * 1999-04-22 2002-07-25 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2006220426B2 (en) * 2000-04-14 2008-10-30 Genentech Inc. Method of administering an antibody
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ATE457741T1 (de) * 2001-12-17 2010-03-15 Univ Cardiff Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
EP2368578A1 (fr) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
DK1648940T3 (en) 2003-07-28 2016-08-15 Genentech Inc Reduction of leaching of protein A during protein A affinity chromatography
CA2536918A1 (fr) 2003-08-26 2005-03-03 Leland Shapiro Compositions et procedes pour molecules de fusion fc de l'alpha-1 antitrypsine
WO2005060368A2 (fr) 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Anticorps humanises anti-ccr2 et leurs procedes d'utilisation
OA13358A (en) 2004-01-09 2007-04-13 Amgen Fremont Inc Antibodies to MAdCAM.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
PL2990422T3 (pl) 2004-09-03 2018-11-30 Genentech, Inc. Humanizowani antagoniści anty-beta7 i ich zastosowania
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007007160A2 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Anticorps anti-madcam servant a traiter la fievre
WO2007007151A2 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Utilisation d'anticorps anti mad-cam dans le traitement de l'emphyseme
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
US20100166747A1 (en) * 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
JP2010521966A (ja) * 2007-03-20 2010-07-01 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN111253484A (zh) 2007-06-25 2020-06-09 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
HUE061746T2 (hu) 2007-07-09 2023-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP2182983B1 (fr) * 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Traitement de maladies amyloïdogéniques avec anti-abeta anticorps humanise
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP3441402A1 (fr) 2007-10-30 2019-02-13 Genentech, Inc. Purification d'anticorps par chromatographie à échange de cations
AU2009203369B2 (en) * 2008-01-11 2014-04-03 Astellas Pharma Inc. Improved humanized anti-human alpha9-integrin antibody
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009151514A1 (fr) 2008-06-11 2009-12-17 Millipore Corporation Bioréacteur à cuve agitée
DK3604324T3 (da) 2008-08-14 2024-04-08 Genentech Inc Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
CN102209554A (zh) 2008-09-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010074953A1 (fr) 2008-12-16 2010-07-01 Millipore Corporation Réacteur à cuve agitée et procédé
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
AU2013205341B2 (en) * 2009-03-20 2016-05-05 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
AU2016208453B2 (en) * 2009-03-20 2018-02-22 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2010107752A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
CA2939492C (fr) 2009-05-13 2019-03-19 Genzyme Corporation Immunoglobulines anti-cd52 humain
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
HUE067718T2 (hu) 2009-10-26 2024-11-28 Hoffmann La Roche Eljárás glikozilált immunglobulin elõállítására
EP2550018B1 (fr) 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Compositions et méthodes pour la stabilisation de formulations contenant une protéine
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
SI2585045T1 (sl) 2010-06-24 2019-11-29 Hoffmann La Roche Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
WO2012030512A1 (fr) 2010-09-03 2012-03-08 Percivia Llc. Procédé de purification de protéine en flux
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
KR102103476B1 (ko) 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
ES2697676T3 (es) 2011-12-22 2019-01-25 Hoffmann La Roche Cromatografía de membrana de intercambio iónico
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
KR20140137347A (ko) * 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
EA201992881A3 (ru) * 2012-01-12 2020-12-30 Милленниум Фармасьютикалз, Инк. Композиция анти-47 антитела
US20140080180A1 (en) 2012-03-27 2014-03-20 Genentech, Inc. Harvest operations for recombinant proteins
CN103374073A (zh) * 2012-04-26 2013-10-30 中国科学院上海生命科学研究院 识别活化形式整合素α4β7的人源化单克隆抗体
JP6254581B2 (ja) 2012-05-18 2017-12-27 ジェネンテック， インコーポレイテッド 高濃度モノクローナル抗体製剤
WO2014100095A1 (fr) 2012-12-19 2014-06-26 Genentech, Inc. Procédés et compositions pour le marquage de protéine par un radiohalogène
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
ES2971041T3 (es) 2014-10-06 2024-06-03 Chemocentryx Inc Terapia combinada de inhibidores del receptor 9 de quimiocina C-C (CCR9) y anticuerpos bloqueadores anti-integrina alfa4beta7 para el tratamiento de la enfermedad inflamatoria intestinal
EP3581585A1 (fr) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab pour le traitement de la fistulisation de la maladie de crohn
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
IL301753A (en) 2015-08-11 2023-05-01 Univ Osaka Antibody
WO2017041001A2 (fr) * 2015-09-04 2017-03-09 The California Institute For Biomedical Research Protéines de fusion immunoglobuline-insuline
US20190008935A1 (en) 2015-12-31 2019-01-10 The Regents Of The University Of Colorado, A Bodo Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
US20190077868A1 (en) * 2016-03-14 2019-03-14 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
CN116327920A (zh) * 2016-03-14 2023-06-27 千禧制药公司 预防移植物抗宿主疾病的方法
WO2017165742A1 (fr) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
EP3433275A1 (fr) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017172994A1 (fr) 2016-03-29 2017-10-05 Geltor, Inc. Expression de protéines dans des bactéries gram négatif, avec un rapport du volume périplasmique au volume cytoplasmique compris entre 0,5:1 et 10:1
EP3452070A1 (fr) 2016-05-04 2019-03-13 Millennium Pharmaceuticals, Inc. Trithérapie pour le traitement d'une maladie intestinale inflammatoire
EP3469069A4 (fr) * 2016-06-10 2020-01-22 Kota Biotherapeutics, LLC Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique
EP3468597A1 (fr) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Méthode de traitement de maladie intestinale inflammatoire
WO2018104893A1 (fr) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Anticorps anti-alpha4-beta7 présentant une liaison à fcrn et/ou une demi-vie augmentées
JP7553241B2 (ja) 2016-12-22 2024-09-18 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
CA3061320A1 (fr) 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Methode de traitement de troubles pediatriques
EP3652211A1 (fr) 2017-07-14 2020-05-20 Pfizer Inc. Anticorps dirigés contre madcam
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
KR102870511B1 (ko) 2018-07-03 2025-10-15 브리스톨-마이어스 스큅 컴퍼니 재조합 단백질 생산 방법
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
CA3121168A1 (fr) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Compositions heterodimeres d'anticorps a specifiques et a tetravalents, et utilisations de celles-ci
WO2020205716A1 (fr) 2019-04-01 2020-10-08 Genentech, Inc. Compositions et procédés de stabilisation de formulations contenant des protéines
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
WO2020215019A1 (fr) * 2019-04-17 2020-10-22 Millennium Pharmaceuticals, Inc. Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23
WO2020252082A1 (fr) * 2019-06-10 2020-12-17 Millennium Pharmaceuticals, Inc. Procédés de culture cellulaire et compositions pour la production d'anticorps
CN118909119A (zh) * 2019-06-10 2024-11-08 武田药品工业株式会社 抗体纯化方法及其组合物
WO2021021973A1 (fr) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Procédés d'amélioration de la productivité de protéines dans des cultures cellulaires à alimentation discontinue
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (fr) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Procédés de régulation du taux d'oxygène dissous (do) dans une solution comprenant une protéine recombinante dans un récipient de stockage
PE20250753A1 (es) 2022-06-16 2025-03-13 Cephalon Llc Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
CN121729428A (zh) 2023-05-30 2026-03-24 派拉冈医疗公司 α4β7整联蛋白抗体组合物和使用方法
WO2024252368A2 (fr) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Procédés et compositions pour le traitement de la rectocolite hémorragique
WO2025137093A1 (fr) 2023-12-19 2025-06-26 Cephalon Llc Utilisations d'immunoconjugués d'il-2 atténués
CN117777292B (zh) * 2023-12-28 2024-10-18 天津大学 抗整合素α4β7纳米抗体及其用途
WO2025149974A1 (fr) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Polythérapie avec un anticorps anti-alpha4bêta7
WO2025177214A1 (fr) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Méthodes thérapeutiques
WO2026058045A1 (fr) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Inhibiteur d'alpha4bêta7 et polythérapie par inhibiteur d'il-23

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3220049A1 (de) 1982-05-27 1983-12-01 Universal Maschinenfabrik Dr. Rudolf Schieber GmbH & Co KG, 7081 Westhausen Strick- und umhaengeschlosskombination fuer v-bett-flachstrickmaschinen mit schiebernadeln
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3852236T2 (de) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992015683A1 (fr) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Anticorps monoclonaux humanises et chimeriques
US5665595A (en) * 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK0625912T3 (da) 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
AU5732694A (en) 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
CA2155303C (fr) 1993-02-09 2010-04-20 Linda C. Burkly Traitement de diabetes a insulinodependance
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
KR100367948B1 (ko) 1994-01-25 2003-07-12 엘란 파마슈티칼스, 인크. 백혈구부착분자vla-4에대한인체화된항체
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin

Also Published As

Publication number Publication date
DE69735596T3 (de) 2016-02-25
LTC0918797I2 (lt) 2017-05-10
CA2263106A1 (fr) 1998-02-19
IL128052A0 (en) 1999-11-30
ATE321788T1 (de) 2006-04-15
US20060292140A1 (en) 2006-12-28
ES2262186T5 (es) 2015-12-11
IL128052A (en) 2006-08-20
DE69735596D1 (de) 2006-05-18
EP0918797A2 (fr) 1999-06-02
DK0918797T4 (en) 2016-01-11
JP2008281562A (ja) 2008-11-20
BRPI9711079B8 (fr) 2021-05-25
JP4171071B2 (ja) 2008-10-22
JP2001507210A (ja) 2001-06-05
CA2263106C (fr) 2010-08-03
JP4578536B2 (ja) 2010-11-10
PT918797E (pt) 2006-08-31
EP0918797B2 (fr) 2015-09-23
ES2262186T3 (es) 2006-11-16
BRPI9711079B1 (pt) 2017-06-20
AU730326B2 (en) 2001-03-01
IL175570A0 (en) 2006-09-05
HK1021822A1 (en) 2000-07-07
SI0918797T1 (sl) 2006-10-31
AU730326C (en) 2005-06-16
JP2010246548A (ja) 2010-11-04
US7147851B1 (en) 2006-12-12
SI0918797T2 (sl) 2016-01-29
LU92596I2 (fr) 2015-01-12
NZ334226A (en) 2000-10-27
WO1998006248A2 (fr) 1998-02-19
WO1998006248A3 (fr) 1998-05-07
DK0918797T3 (da) 2006-07-31
EP0918797B1 (fr) 2006-03-29
US7402410B2 (en) 2008-07-22
US20090011464A1 (en) 2009-01-08
AU3972897A (en) 1998-03-06
DE69735596T2 (de) 2006-12-21
JP5166483B2 (ja) 2013-03-21
EP1710314A1 (fr) 2006-10-11
CN100406562C (zh) 2008-07-30
CN1227607A (zh) 1999-09-01
BR9711079A (pt) 2000-06-06

Similar Documents

Publication Publication Date Title
BE2014C068I2 (fr)
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
GB2250995A (en) Multivalent antigen-binding proteins
WO1999037681A3 (fr) Procede servant a preparer des fragments d'anticorps
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
EP1362868A3 (fr) Anticorps monoclonaux humanisés et chimériques se liant au récepteur du facteur de croissance épidermique (EGF-R)
DE69000338D1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
WO1995024481A3 (fr) Anticorps monoclonaux humanises contre l'interleukine-4 chez l'homme
WO1998012334A3 (fr) Anticorps chimeres humanises a chaine unique contre l'alpha-2-antiplasmine
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты